"Bind-Engulf-Destroy"

NanoViricides Incorporated

Stock Symbol:
NNVC
(NYSE American)

A Revolutionary Strategy for Viral Infections

Emperic Treatment with NV-387 is Possible

Just Like Emperic Treatment of Bacterial Infections Became Possible with Penicillin

Presentation at the
BIO International Convention 2025
June 16, 2025
Boston Convention & Exhibition Center (BCEC), Boston, MA

Presented by:
Anil R. Diwan, PhD
President & Exec. Chairman
adiwan@nanoviricides.com

Disclosure Statement

NanoViricides, Inc. is a NYSE-American listed publicly traded company (stock symbol: NNVC).

This is not an offering memorandum and should not be construed as such. It is provided as a non-confidential document for informational purposes only.

NanoViricides, Inc.(www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, perpetual field licenses to all drugs developed in the licensed field areas (virus indications) from TheraCour Pharma, Inc. The Company obtains additional licenses after determining that it intends to pursue a drug candidate in the licensed field into commercialization. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, covering all drugs for the licensed application, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company") regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities18 Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Imagine Emperic Treatment for Viral Infections

If the Doctor Could Treat a Patient with Viral Infection Right Away
With an Antiviral
Without Having to Test For, Wait for Test, and Decipher
Which Virus is Causing Disease

After All, That's How Bacterial Infections Are Treated Right Away
with Antibiotics, Even Before (Without) Knowing
Which Bacterium is Causing Disease

NanoViricides is Making It Possible
with the Clinical Stage Broad-Spectrum Antiviral, NV-387

NV-387 Atttacks Viruses Across Many Boundaries

Viruses - Baltimore Classification							
DNA Viruses			**RNA Viruses**				
I. dsDNA	**II. ssDNA**	**VII. DNA-RT**	**III. dsRNA**	**IV. (+)ssRNA**	**V. (-)ssRNA**		**VI. RNA-RT**
					MonoNegaVirale	Segmented	RetroViridae
HerpesV. =	CircoV.	Hepatitis B	ReoV.	**CoronaV. =**	ParamyxoV.=	FiloV. =	**InfluenzaV.**	HIV
HSV-1, HSV-2, VZV EBV, CMV HHV-6A, 6B, 7	ParvoV.	HepadnaV.	RotaV.	SARS-I,II, MERS NL63, OC43, 229E,	**RSV** Measles HendraV, NipaV. PIV	Ebola, Marburg	ArenaV. =	HTLV
			IV. (+)ssRNA			RhabdoV. =	Lassa	SpumaV.
			(Unenveloped) PicornaV. =	FlaviV. =		LyssaV. (Rabies, Mokola)	Junin	
PoxV. (MPox, SMallpox)			PolioV, CoxSackieV, EnteroV, EchoV, hFMDV, RhinoV.	DENV-I to IV, Zika, WNV HCV		VesiculoV. =	BunyaV.	
AdenoV. (Many)						VSV, Chandipura	RFV	
PolyomaV. (JCV, BKV)				TogaV./ AlphaV. - Chik, EEEV.			Hanta	
Notes:	**Viruses for which NV-387 has Demonstrated Activity Are in This Color**				**Some Sulfated-Proteoglycan Attachment Factor Viruses Expected to be Susceptible to NV-387 Are in This Color**			

NV-387, A SPG-Mimetic Nanoviricide Is Effective in Lethal Animal Models and is Superior to Existing Drugs Against a Diverse Family of Viruses

Virus Family	Virus	Animal Model	Survival	Comparative Survival Improvement
Coronaviruses	**hCoV-NL-63 (SARS-CoV-2 Surrogate)**	Rat Lethal Lung Infection	NV-387, IV = 14 Days NV-387, PO = 8.4 Days VS. Remdesivir/SBECD, IV = 7 Days Vehicle, IV = 5 Days	**NV-387, IV = 450%** **NV-387, PO = 170%** **Taking RDV = 100%**
RSV	**RSV, A2**	Balb-c Mice Lethal Lung Infection	NV-387, PO = 22 Days (Full Survival) VS. Ribavirin, PO = 13.8 Days Vehicle, PO = 7 Days	**NV-387, PO Led to Full Survival** **Ribavirin Increased Survival by ~ 7 Days**
Influenza	**H3N2 (A/ California/ 2/2014)**	Balb-c Mice Lethal Lung Infection	NV-387, IV = 16 Days NV-387, PO = 15 Days VS. Peramivir, IV = 11 Days Oseltamivir, PO = 11 Days Baloxivir, PO = 11 Days Vehicle, IV & Vehicle, PO = 8 Days	**NV-387, IV = 265%** **NV-387, PO = 233%** **Taking All 3 of Peramivir, IV; Oseltamivir, PO; and Baloxivir, PO = 100%**
Orthopox Viruses (Smallpox/ MPox)	**Ectromelia**	SCID-Balb-c Lethal Lung Infection	NV-387, PO = 14 Days NV-387-m-T, PO = 16 Days VS Tecovirimat, PO = 11 Days Vehicle, PO = 7 Days	**NV-387, PO = 175%** **NV-387-m-T, PO = 225%** **Taking Tecovirimat, PO = 100%**
* Notes:		* NV-387-m-T: Tecovirmat Mixed into NV-387 demonstrates the orthogonal mechanisms enable improved effect, of the two taken together. * * NV-387 “Plays Nice” with Existing Drugs when Given Together : Orthogonal Mechanism of Action		

NanoViricides Technology Platform Defines A Novel Paradigm : Cell-Mimicking Nanomachines that Seek to Bind, Encapsulate and Destroy a Virus Particle Without Immune System Assistance

A Virus Uses Specific Cellular Receptor(s).
Viral Coat Protein Mutates Readily;
But Binds to the Same Site(s) on Its Cellular Receptor(s).





Small Chemical Ligands :  **that Mimick the "Key" Invariant Virus Binding Site on Cellular Receptor(s) Drive Binding to Virus.**

Polymeric Micelle with Pendant Lipid Core and Amphiphilic PEG-based Shell Drives Lipid-Lipid Fusion with Virus Envelope and Destabilization of the Particle.



- Bind the Virus Particle at Multiple Points, "NanoVelcro" Effect (Stages #1,2,3)
- Engulfment of the Virus Particle by "Shape-shifting" Nanoviricide Micelle would Render the Virus Particle Incapable of Infecting Cell (stage #4)

Complex Virus LifeCycle Enables Many Strategies for Attack

- All Viruses Must Infect Cells
  - BIND to ATTACHMENT RECEPTOR(s)
  - TRANSFER to COGNATE RECEPTOR(s)
  - FUSE OR (PINO/ENDO)-CYTOSE INTO CELL
- All Viruses Must Replicate Within Cells
  - UNCOAT in CELLULAR COMPARTMENT
  - ASSEMBLE VIRAL and HOST MACHINERY
  - CLONE GENOME
  - REASSEMBLE VIRAL PARTICLE
- and Successfully Exit Cells
  - Without Killing Cell or by Destroying Cell
- To Succeed, The Virus Must Dysregulate Host Immune System

After Primary Infection of Host from External Sources;
for Infection to Take Hold
Viruses Effectively Hijack Human System, Multiply, Exit, and Spread in Population

Viruses Have Evolved Diverse Strategies for Each of the LifeCycle Events Making it Very Difficult to Design & Develop a Drug that Works Against a Large Number of Viruses

Nucleo(s)(t)ide Inhibitors, although Broad Spectrum, In Practice, They Have Dose-Limiting Toxicities that Limit Effectiveness and Usability

The "Achilles Heel(s)" of the Virus

THE ENTRY MECHANISMS OF VIRUSES, HOWEVER, CAN YIELD SAFE AND EFFECTIVE, BROAD-SPECTRUM DRUG STRATEGIES, DRUGS THAT THE VIRUS CANNTO ESCAPE

- Even As a Virus Mutates Rapidly (or Slowly), including in its Receptor Interaction Regions; the Site on the Receptor to which it binds DOES NOT CHANGE Much
- Enabling Drugs that the Virus Cannot Escape!
- Cognate Receptors are Virus-Type/Subtype Specific (e.g. SARS-CoV-2 uses ACE2, HIV Uses CD4); Spectrum of Drugs Mimicking Such Sites would be that of the Virus-Type/Subtype and almost all mutants
- Same Classes of Attachment Receptors are Broadly Employed by Many Diverse Virus Families!
- Mimicking Attachment Receptor Features Used by Viruses would Enable Ultra-Broad-Spectrum Drugs
- Ideal for Pandemic Preparedness!

Just mimicking the Attachment Factor is Not Enough! Must Design the Mimetic to Destroy the Virus!

NanoViricides Technology Differentiation

	Nanoviricide Drug	Antibodies	Other Drugs	Vaccines
Mechanism	**Re-Infection Inhibition (Novel)**	Neutralization	Replication Inhibition	Antibodies Generation
Therapeutic Post-Infection?	**Yes**	**Yes**	**Yes**	**No**
Viral Resistance	**Unlikely**	**Rapidly**	**Eventually**	**Rapidly**
Cure Possible for Non-Latency Viruses?	**Yes**	**No**	**No**	**No**
Broad Spectrum?	**Yes**	**No**	**No/Maybe**	**No**
Immune-Compromised Patients?	**Yes**	**No/Maybe**	**Yes**	**No**
Oral Dosing?	**Yes**	**No**	**Yes/Maybe**	**No/Maybe**
Infrequent Dosing?	**Yes**	**No**	**No**	**Yes**
Easy Compliance	**Yes**	**No**	**No**	**No**
No Need for Infusion	**Yes**	**No**	**Yes**	**Yes**
No or Minimal Side Effects	**Yes**	**No**	**No**	**No** (Due to Large Numbers)
Safe (Allergy, Mutagen, Immunogen, Genotox)	**Yes**	**No** (Immune Reactions)	**No** (Often Mutagenic)	**No** (Immune Reactions, Allergy)
Storage and Supply Chain Conditions	**RT, 2-8°C**	**2-8°C**	**RT**	**-20°C**
Can Encapsulate Another API	**Yes**	**No**	**No**	**No**

NV-387 Pre-clinical Safety/Toxicology and PharmacoKinetics

- **Orally Bioavailable Drug Candidate ~25~40% Bioavailability, Based on Equivalent Effect Compared to Injected Doses**
- Pre-clinical Safety Suggestive of Usability in All Demographies; Pediatrics; At-Risk Patients…
  - **NOAEL 1,200 mg/Kg and MTD 1,500 mg/Kg in Rats I.V. (Non-GLP)**
  - No observations in Cardiotoxicity in Cynomolgus Monkeys (GLP)
  - No observations in Neuro-Pulmonary Toxicology in Rats (GLP)
- Additional Safety Pharmacology:
  - Non-Immunogenic in Rats (Non-GLP)
  - Non-Mutagenic in Bacterial Mutagenesis Test (Ames) (GLP)
  - Non-Genotoxic in *in vitro* MicroNucleus Test (MNT) (GLP)
  - No Injection-Site Reactions in Multiple Slow-Injections in Rats, Mice, NHP
  - Data Indicative of Primarily Fecal Clearance

NV-387 Has Completed Phase I Clinical Trials Successfully

- **Oral Gummies and Oral Syrup Formulations**
- Up to 80 mg/Kg single dose
- Multiple Dosing - 6 Doses over 9 Days
  - Cumulative Total Max 240 mg/Kg
  - 6 Subjects per Cohort, Total 36 Subjects
- **All Healthy Subjects 36/36 Phase 1a SAD, and 36/36 Phase 1b MAD-Healthy Have Completed the Study - No Dropouts.**
- **No Reported Adverse Events - No AEs, SAEs, or ADRs Found**
- **Clinical Signs, Blood Chemistry, Heart Monitoring Etc. All Normal**
- **Now Preparing for Phase II**

NanoViricides is a Unique Drug Developer Company with Its Own cGMP-Compliant Nanomedicines Manufacturing Capability Clinical Product Supply Capability

- Drug Substance Capability - Clean Rooms - 5~10 Kg/Batch, 100L
- Drug Products - Fill-Finish-Package CleanRoom Suites
- Skin Creams, Eye Drops, Gels, Injectables, Oral…
- Nanomedicines Characterization Facility
- Protect Proprietary Technology & Intellectual Property
- Rapid Transfer from Lab Bench to cGMP Manufacture
- Highly Customizable Flexible Pharma Manufacturing Capability
- Significant Time and Cost Savings
- Potential for Manufacturing Commercial Product: Market Entry & Early Revenues
- Also Have Own BSL2 Virology Lab

NanoViricides Drugs Pipeline

	Drug Substance	Indication	Lead Id.	Animal Efficacy Eficacy	IND-Enabling Studies	Phase I	Phase II	Phase III
1	NV-387	RSV						
2		COVID						
3		MPox/Smallpox						
4		Influenza						
5	NV-HHV-1 (Skin Cream)	Shingles (VZV)						
6		Cold Sores (HSV-1)						
7		Genital Ulcers (HSV-2)						
8	NV-HIV-1	HIV/AIDS						
9*	NV-387-g-X	DNA Viruses						
10*	NV-387-g-Y	RNA Viruses						
>	Several Additional R&D Programs in Progress							



*** #9 and #10 are Advanced Development Programs to Develop Cures for Most DNA and RNA Viral Infections, respectively.**

X and Y are Proprietary, Patentable Chemicals Designed to Block the Replication Part of the Lifecycle of the Virus, While NV-387 Itself Is Designed to Block the Re-Infection Part of the Virus Lifecycle.
Thus the Drugs NV-387-g-X and NV-387-g-Y Would Block the Complete Virus Lifecycle of DNA and RNA Viruses Respectively.

"g" Refers to Encapsulation of the Guest (X or Y) Within the NV-387 Nanomicelles.

Strong Executive Team

Anil R. Diwan, PhD
President & Exec. Chairman

Co-Founder
Led Uplisting to NYSE-American Exchange in 2013
Raised Over $120M
Co-Inventor of Nanoviricides® & of TheraCour ®
25+ years Leadership & Entrepreneurial experience
Key Patents, Several NIH SBIR Awards
PhD (Biochem Eng - Rice), BTech (ChemEng - IITB)
Ranked 9th All India on JEE to IITs (1975)

Krishna Menon, VMD, MRCS, PhD
Consulting Pre-Clinical Studies

30+ Years of Pharmaceutical Industry Experience in Drug Discovery and Pre-clinical Regulatory Development
Eli Lilly President's Award

AZT, GemCitabine, Pemetrexed (Alimta) Development

Eli-Lilly, Dana-Farber, Beth-Israel, Bayer Alumnus

Meeta R. Vyas, MBA
CFO

30+ years Experience in Corporate Performance Improvement, Finance, M&A, EBITDA Growth...
Previously: Principal, The Gores Group; Director, Kamylon Capital; CEO, Signature Brands, Inc. (a public company, known for "Mr. Coffee"); Ran $1B GE Appliances Division; Consultant, McKinsey & Company

MBA (Finance) Columbia U, BS (ChemEng) MIT

Jayant Tatake, PhD
VP, R&D

30+ Years of Pharmaceutical Industry Experience in Drug Discovery, Manufacturing, QA/QC, CRO, Synthesis, Scale-up, Formulations, and Pharmaceutical cGMP Expertise

Former Asst. Director, Pharma. Analytics, InterPharm, Inc.
Co-Inventor of Nanoviricides® & TheraCour®
PhD, UICT, Mumbai, India

Board of Directors

Anil R. Diwan, PhD
President & Exec. Chairman

Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised $100M+, Co-Inventor of Nanoviricides® & of TheraCour ®
30+ years Leadership & Entrepreneurial experience

Not an Independent Board Member
Director and Chairman Since Founding in 2005

Mak Jawadekar, PhD ✔

35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D.
Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

Independent Board Member since February, 2020

Hon'ble Theodore "Todd" Rokita, JD ✔

Presently Attorney General, State of Indiana. Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

Independent Board Member since May, 2020

Brian M. Zucker, CPA ✔

30+ years of experience as a CPA specializing in the securities industry. A Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/). Also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. Partner at RRBB Accountants & Advisors. CFO of EIG Energy Partners Capital Markets, LLC. Ex-Senior Consultant at Deloitte Haskins & Sells and at Price Waterhouse. Mr. Zucker holds several FINRA licenses.

Independent Board Member since November, 2020

✔ = Independent Board Member

NanoViricides Incorporated

"Nanotechnology-Enabled Targeted Viricides"
A Publicly Traded Company, "NNVC"
www.nanoviricides.com

Thank you for your attention and guidance.

Please address additional inquiries/correspondence to:

Anil R. Diwan, Ph.D.
President & Executive Chairman
NanoViricides, Inc.
Office:
1 Controls Drive
Shelton, CT 06484.
Mobile Phone:
+1 (203) 606-9180
Email:
adiwan@nanoviricides.com

Together We Can Destroy Viruses